These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11069435)

  • 1. Drugs used in secondary prevention after myocardial infarction: case presentation.
    Maxwell S; Waring WS
    Br J Clin Pharmacol; 2000 Nov; 50(5):405-17. PubMed ID: 11069435
    [No Abstract]   [Full Text] [Related]  

  • 2. [Secondary prevention in patients after myocardial infarction by means of Tromcardin forte (author's transl)].
    Geizerová H; Widimský J
    Cas Lek Cesk; 1974 May; 113(21-22):672-7. PubMed ID: 4615795
    [No Abstract]   [Full Text] [Related]  

  • 3. An early intervention secondary prevention study with oxprenolol following myocardial infarction.
    Eur Heart J; 1981 Oct; 2(5):389-93. PubMed ID: 7037414
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of patients after their first myocardial infarction.
    Flapan AD
    BMJ; 1994 Oct; 309(6962):1129-34. PubMed ID: 7987108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary prevention of myocardial infarction: new horizons for pharmacotherapy. Introduction.
    Taylor SH
    Eur Heart J; 1996 Dec; 17 Suppl F():1-2. PubMed ID: 8960441
    [No Abstract]   [Full Text] [Related]  

  • 6. Which patients should receive beta-blocking drugs after myocardial infarction?
    Taylor SH
    Eur Heart J; 1983 Jul; 4 Suppl D():161-6. PubMed ID: 6137378
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.
    Van de Werf F; Ardissino D; Betriu A; Cokkinos DV; Falk E; Fox KA; Julian D; Lengyel M; Neumann FJ; Ruzyllo W; Thygesen C; Underwood SR; Vahanian A; Verheugt FW; Wijns W;
    Eur Heart J; 2003 Jan; 24(1):28-66. PubMed ID: 12559937
    [No Abstract]   [Full Text] [Related]  

  • 8. [Heparin in the treatment and secondary prevention of myocardial infarction. A critical review of the main trials].
    Kher A; Samama M; Haïat R
    Arch Mal Coeur Vaiss; 1991 Nov; 84(11):1581-6. PubMed ID: 1662479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
    Prescrire Int; 1999 Aug; 8(42):116-20. PubMed ID: 11503831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Office care of patients after myocardial infarction.
    Derby RC; Reamy BV; Plumley RL
    Postgrad Med; 2008 Apr; 120(1):11-7. PubMed ID: 18467804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Beta-blockers and secondary prevention after myocardial infarction].
    Kher A; Jaillon P
    Therapie; 1984; 39(2):189-96. PubMed ID: 6145232
    [No Abstract]   [Full Text] [Related]  

  • 12. Trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction.
    Elwood P
    Br Med J (Clin Res Ed); 1981 Feb; 282(6262):481. PubMed ID: 6780093
    [No Abstract]   [Full Text] [Related]  

  • 13. [Adrenergic beta receptor blockaders as a secondary prevention after acute myocardial infarction].
    Jensen G; Sigurd B
    Ugeskr Laeger; 1981 Nov; 143(48):3241-5. PubMed ID: 6120594
    [No Abstract]   [Full Text] [Related]  

  • 14. Secondary prevention of myocardial infarction with drugs.
    Klimt CR; Forman SA
    Isr J Med Sci; 1983 May; 19(5):460-70. PubMed ID: 6134697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiac rehabilitation: a plus value for secondary prevention?].
    Scardi S; Mazzone C
    Monaldi Arch Chest Dis; 2003 Mar; 60(1):1-6. PubMed ID: 12827827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European infarction study (EIS). A secondary prevention study with slow release oxprenolol after myocardial infarction.
    Eur Heart J; 1982 Dec; 3(6):583-6. PubMed ID: 6761123
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical trials in thrombosis: secondary prevention of myocardial infarction.
    Klimt CR; Doub PH; Doub NH
    Thromb Haemost; 1976 Feb; 35(1):49-56. PubMed ID: 785688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary prevention with calcium channel-blocking drugs in patients after myocardial infarction: a critical review.
    Moss AJ
    Circulation; 1987 Jun; 75(6 Pt 2):V148-53. PubMed ID: 3552311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presentation and analysis of the results of clinical trials in cardiovascular disease.
    Hampton JR
    Br Med J (Clin Res Ed); 1981 Apr; 282(6273):1371-3. PubMed ID: 6786503
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of pharmacotherapy in secondary prevention of myocardial infarction and death.
    Gorlin R; Fuster V
    Mt Sinai J Med; 1984 Jun; 51(3):229-36. PubMed ID: 6146929
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.